{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-051957","form_type":"8-K","ticker":"VRCA","cik":"0001660334","company_name":"Verrica Pharmaceuticals Inc.","filed_at":"2025-03-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.349273+00:00","generated_at":"2026-05-24T23:46:10.810154+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Verrica Q4 product revenue $0.3M, net loss $0.24/sh; YCANTH units up 12.3% sequentially","bullets":["Q4 product revenue $0.3M (vs $1.9M in 2023); FY product revenue $6.6M (vs $4.7M) with $3.2M returns reserve.","Q4 GAAP net loss $16.2M ($0.24/sh) vs $24.6M ($0.53/sh); FY loss $76.6M ($1.48/sh) vs $67.0M ($1.48/sh).","YCANTH dispensed units 8,654 in Q4 (+12.3% QoQ); operating expenses cut ~50% after restructuring with $1.0M charge.","Cash $46.3M at Dec 31; $8M Torii milestone upon Phase 3 common warts start and $25M Series A warrants could extend runway; GAAP raises going concern doubt.","VP-315 Phase 2 shows 97% ORR and ~51% complete histological clearance; Phase 3 for common warts could begin mid-2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-051957","json":"https://secwatch.observer/filing/0001193125-25-051957.json","markdown":"https://secwatch.observer/filing/0001193125-25-051957.md","text":"https://secwatch.observer/filing/0001193125-25-051957.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1660334/000119312525051957/0001193125-25-051957-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1660334/000119312525051957/d937567d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T23:46:10.810154+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}